Trends in the use of antipsychotics in the Israeli inpatient population, 2004–2013

Alexander M. Ponizovsky1,4*, Eli Marom2, Michal Ben-Laish2, Igor Barash1, Abraham Weizman3 and Eyal Schwartzberg2

Abstract

Background: Although serious mental illnesses are treated with both typical and atypical antipsychotic drugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the use of typical and atypical antipsychotic drugs in the Israeli inpatient psychiatric population throughout the last decade.

Methods: Data regarding allocation of typical and atypical antipsychotics, over the period 2004 to 2013, were extracted from the electronic records of SAREL, Israel’s largest private supplier of drugs to healthcare and medical facilities. The data were converted to defined daily doses (DDD) per 1000 inpatients per day.

Results: Usage of the ten atypical antipsychotic agents allocated through Israel’s national health care system increased by 73%, from 128.09 DDD/1000 inpatients/day in 2004 to 221.69 DDD/1000 inpatients/day in 2013. This rise from 2004 to 2013 was largely due to a 1.6-fold increase in the administration of olanzapine (48.31 to 79.57 DDD/1000 inpatients/day), a 4.4-fold increase of quetiapine (9.74 to 43.04 DDD/1000 inpatients/day) and 3.7-fold increase of amisulpride (5.54 to 20.38 DDD/1000 inpatients/day). At the same period, the total utilization of 12 main typical antipsychotics decreased by 15.5%, from 148.67 DDD/1000 inpatients/day in 2004 to 125.57 DDD/1000 inpatients/day in 2013. Over the entire period, total DDDs of both classes of antipsychotics (typical and atypical) increased by 38%.

Conclusions: Similar to trends in the treatment of psychiatric outpatients in other countries, there was a substantial increase in the administration of atypical antipsychotic drugs to the Israeli psychiatric inpatient population across the study period. A decrease in the use of typical antipsychotics (substitution), polypharmacy, administration for more indications (supplementation) and the use of larger doses of antipsychotics may account, in part, for this increase. The findings have implications for mental health policy in the context of the Mental Health Care System Reform. Systematic studies on appropriate dosing of antipsychotics and augmentation strategies are warranted.

Keywords: Atypical antipsychotics, Typical antipsychotics, Sertindole, Ziprasidone, Clozapine, Olanzapine, Quetiapine, Amisulpride, Risperidone, Aripiprazole, Paliperidone, Iloperidone, Pharmacoepidemiology

Background

Serious mental illnesses (SMI), such as schizophrenia, schizoaffective and bipolar disorders, are chronic medical disorders with unknown etiology, complex pathophysiology and polymorphic symptomatology. Mental, emotional and behavioral manifestations of the disorders result in serious functional impairment, substantially interfering with or limiting one or more major life activities and in turn decreasing quality of life of the patients. Until the mid-1990s only conventional antipsychotic drugs (typicals or first-generation antipsychotics) were used to treat SMI. Atypical antipsychotics (atypicals or second-generation antipsychotics) are currently the first-line treatments for schizophrenia [1, 2] and the recommended maintenance option for bipolar disorder [3, 4]. Both typical and atypical antipsychotic agents block brain dopamine receptors and have comparable efficacy, but atypicals have a safer profile of neurological side-effects: they are less likely to cause extrapyramidal symptoms and tardive dyskinesia [5]. However, atypicals may cause serious metabolic side-effects such as significant weight gain, dyslipidemia and sometimes diabetes mellitus [6].
Since their introduction in the mid-1990s, there has been a proliferation of atypical antipsychotics and there are currently at least 15 atypicals available in psychiatric practice in developed countries [7, 8]. According to the ATC classification index [9], atypicals belong to four chemical groups: 1) indole derivatives (N05AE): sertindole and ziprasidone; 2) diazepines, oxazepines, and thiazepines (N05AH): clozapine, olanzapine, and quetiapine; 3) benzamides (N05AL): amisulpride, and 4) other antipsychotics (N05AX): aripiprazole, iloperidone, paliperidone and risperidone. The introduction of each new atypical antipsychotic agent was accompanied by intense debates among clinicians and researchers regarding the efficacy, side-effect profiles and cost efficiency of the various new drugs [7]. Head-to-head comparisons of atypical antipsychotics lead to the conclusion that atypicals are not a homogenous class [7, 8]. Prescription patterns and, consequently, administration rates of these medications are most likely related to differences in the properties of the atypicals. Clinicians’ prescribing preferences also take into account cost, healthcare policies, marketing, public perceptions, etc.

Over the past decade, several pharmacoepidemiological studies exploring trends in prescription and administration of psychotropic drugs (including atypical antipsychotics) were conducted in different countries [10–13]. Trends were reported for special (e.g., children) and non-institutionalized (ambulatory) populations and were explained either by escalating off-label use or regulatory approval for indications other than schizophrenia and related psychoses [14], such as bipolar mania and depression [15], control of aggression, ADHD and conduct disorders in children [16] and behavioral problems in elderly patients with dementia [17]. In addition, there are a few studies that assessed antipsychotic drug use in inpatient settings [18, 19]. Findings revealed that although the use of atypical antipsychotics dominated inpatient practice, total antipsychotic dosing had not increased from 1998 to 2002 [18]. In ambulatory settings, from 2004 to 2009 total antipsychotic doses increased by 97 %, with better clinical improvement and without apparent increase in major side-effects [19]. Unfortunately, an analogous investigation was not carried out in Israel. Our choice of the targeted population was based on both the availability and reliability of the data on the use of atypicals by psychiatric inpatients and the availability of reliable statistics of psychiatric admissions over the study period.

The psychiatric hospitalization system in Israel includes ten psychiatric hospitals and twelve psychiatric wards in general hospitals. These services provide inpatient care or day hospitalization according to the severity of the patient’s condition. Despite major reform in the patterns of mental health care which resulted in a massive reduction in the number of inpatient beds - from 0.79/1000 population in 2004 to 0.42/1000 population in 2013, the numbers of persons hospitalized yearly over this period declined by only 2.9 % from 18,286 in 2004 to 17,736 in 2013 [20]. Health insurance in Israel is mandatory and is provided by major health maintenance organizations. The drugs covered by the mandatory insurance are included in the National List of Health Services (NLHS). All antipsychotic agents recommended as first-line treatment (except for sertindole) for SMI, are included in the health service list of approved medications. Findings from this study could have important implications for mental health policymakers and cross-country comparisons.

The primary aim of this study was to detect trends in the use of typical antipsychotics (perphenazine, thioridazine, clozapine, levomepromazine, fluphenazine, proprazazine,chlorpromazine, haloperidol, flupentixol, zuclopenthixol, pimozide, and sulpiride) and atypical antipsychotics (sertindole, ziprasidone, clozapine, olanzapine, quetiapine, amisulpride, risperidone, aripiprazole, paliperidone and iloperidone) in the Israeli inpatient psychiatric population throughout the last decade. The second aim was to assess the possible contributors to the trends in the use of antipsychotics. Namely, if there is an increase in use of atypicals, does this occur entirely at the expense of typicals (substitution), or does the introduction of atypicals actually expand the total use of antipsychotics (supplementation)? The latter could occur if psychiatrists are willing to use atypicals for patients or indications where they were reluctant to use typicals.

**Methods**

Drug utilization data were derived from the database maintained by SAREL which is the largest private supplier of drugs to health maintenance organizations and medical facilities in Israel. The company is the only provider of all atypical antipsychotic formulations (allocated by the National Health Insurance system) to all psychiatric hospitals and psychiatric departments in general hospitals in Israel. Data on the total annual administration of the medications (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone) were evaluated for the years 2004–2013. In addition, we analyzed consumption of four other atypicals – sertindole, paliperidone, aripiprazole, and iloperidone that have been marketed in Israel since 2008, 2009, 2011 and 2013, respectively. In parallel to the analysis of the trends in total administration of atypical antipsychotics, we also analyzed the changes in typical antipsychotics over the same period. Dosages for all drugs were converted to defined daily doses (DDD) per 1000 psychiatric inpatients per day, which is the average maintenance dosage as defined by the World Health Organization Collaborating Center for Drug Statistics [21]. DDDs are based on the ATC classification index. [9]

To calculate administration rates, we used the formula "number of DDD per 1000 psychiatric inpatients per day = number of packages dispensed × number of doses per package × number of mg per dose × 1000 psychiatric
inpatients/DDD in mg x number of psychiatric patients in Israel for the year x 365 days. Data regarding the total population of psychiatric patients (both inpatients and those in day hospitalization) for each year studied were obtained from the corresponding administrative databases maintained by the Department of Information and Evaluation in the Ministry of Health [20, 22]. The retrospective study did not require Institutional Review Board approval because of the anonymous nature of the data used (without patient ID codes) (Table 1 and Fig. 1).

**Results**

Over the study period, the total annual administration of atypical antipsychotics allocated by Israel’s national health care system increased by 73%, from 128.09 in 2004 to 221.69 DDD/1000 inpatients/day in 2013. Table 1 and Fig. 1 show that the administration of olanzapine increased by a factor of 1.6, from 48.31 in 2004 to 79.57 DDD/1000 inpatients/day in 2013. The corresponding figures for quetiapine demonstrated a 4.4-fold increase, from 9.74 DDD/1000 in 2004 to 43.04 DDD/1000 inpatients/day in 2013 and for amisulpride a 3.7-fold increase, from 5.54 in 2004 to 20.38 DDD/1000 inpatients/day in 2013. During the same period, clozapine administration increased by 15%, whereas risperidone administration decreased by 18%. There was also a 3-fold reduction in ziprasidone administration. For more recently marketed drugs, there was nearly a 9-fold rise in paliperidone administration, from 1.34 in 2009 to 11.98 DDD/1000 inpatients/day in 2013. However, its portion of total typical antipsychotic consumption was small. Table 3 shows that for the study period the ratio of atypical to typical antipsychotics usage (expressed in percentages) has changed significantly in favor of atypical medications, from 46.3/53.7% in 2004 to 63.8/36.2% in 2013.

Table 1 Consumption in defined daily dose per 1000 psychiatric inpatients per day of ten atypical antipsychotics covered by Israel’s national health care system, 2004 - 2013

|          | 2004  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  |
|----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Olanzapine | 48.31 | 44.69 | 65.79 | 55.85 | 55.14 | 64.48 | 47.39 | 58.04 | 89.50 | 79.57 |
| Clozapine  | 34.87 | 27.03 | 45.02 | 28.44 | 30.08 | 41.07 | 31.59 | 38.40 | 44.85 | 40.22 |
| Quetiapine | 9.74  | 17.01 | 21.60 | 20.73 | 24.90 | 32.04 | 28.63 | 28.71 | 45.97 | 43.04 |
| Risperidone| 21.61 | 26.86 | 26.37 | 33.99 | 23.35 | 25.16 | 19.52 | 19.86 | 23.02 | 17.79 |
| Paliperidone| 1.34  | 3.42  | 5.26  | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 |
| Aripiprazole| 4.04  | 5.53  | 5.90  | 5.90  | 5.90  | 5.90  | 5.90  | 5.90  | 5.90  | 5.90  |
| Iloperidone| 0.03  | 0.03  | 0.03  | 0.03  | 0.03  | 0.03  | 0.03  | 0.03  | 0.03  | 0.03  |
| Amisulpride| 5.54  | 6.03  | 8.57  | 7.71  | 9.41  | 9.33  | 11.29 | 16.92 | 23.92 | 20.38 |
| Ziprasidone| 8.02  | 4.77  | 3.42  | 3.18  | 3.53  | 3.28  | 3.24  | 4.20  | 4.26  | 2.69  |
| Sertindole | 0.36  | 1.01  | 0.35  | 0.11  | 0.24  | 0.24  | 0.11  | 0.24  | 0.11  | 0.11  |
| Total     | 128.1 | 126.4 | 170.8 | 149.9 | 146.8 | 177.7 | 145.4 | 175.5 | 250.3 | 221.7 |

The blanks correspond to the periods in which the drugs were not marketed.
Regarding the substitution/supplementation question, it was found that over the entire period, total DDDs of both classes of antipsychotics (typical and atypical) increased by 38%. This shows that in addition to the substitution that is already noted (i.e., the decline in typicals’ share), there was also a supplementation which expanded overall use of antipsychotics.

**Discussion**

We investigated the trends in the administration of both typical and atypical antipsychotic drugs in the inpatient population in Israel over the last decade. Results show a substantial increase in the total administration of atypicals, with olanzapine, quetiapine and amisulpride and, recently, aripiprazole and paliperidone accounting for the increase. The administration of older atypicals rose only slightly (e.g., clozapine) or was even somewhat reduced (e.g., risperidone). The growth of atypicals represents both substitution and supplementation, since atypicals’ share increased but so did the overall use of antipsychotics (increased by 38%). It appears that there was not only substitution of typicals by atypicals, but also use of atypicals for patients or indications in which psychiatrists were reluctant to use typicals.

Similar trends towards increase in the utilization of atypicals have been reported in other countries [12]. For instance, there was 217% increase between 2000 and 2011 in Australia; [13] the proportion of prescriptions for atypicals rose from 7% to 96% between 1996 and 2001 in the United States [16] and from 0% to 78% between 1999 and 2005 in Spain [10]. However, unlike our study, the trends were reported for special (e.g., children) and non-institutionalized (ambulatory) populations. The rise in atypicals can be explained by both patterns (substitution...
and supplementation) [10, 12, 16]. The pattern of supplementation was reflected by either escalating off-label use or regulatory approval for indications other than schizophrenia and related psychoses [14], such as bipolar mania and depression [15], for the control of aggression, ADHD and conduct disorder in children [16] and behavioral problems in elderly patients with dementia [17]. The trends for the increased administration of atypicals to the inpatient population in our study may be explained by some of the above factors, although we focused only on hospitalized patients rather than outpatients.

Comparative efficacy and tolerability of each individual drug should be considered when explaining the more extensive use of certain atypicals. In this respect, a recent multiple-treatment meta-analysis comparing RCTs of 15 antipsychotics [8] provides evidence-based hierarchies for the drugs. According to that analysis, clozapine is significantly more effective than all the other antipsychotics, followed by amisulpride, olanzapine and paliperidone. Clozapine was found to produce fewer extrapyramidal side-effects than all other drugs followed by sertindole, olanzapine and quetiapine, whereas risperidone and

![Fig. 3 Relative consumption trends across the ATC atypical antipsychotic drug groups](image)

**Table 2** Consumption of typical antipsychotics covered by Israel’s national health care system, 2004 – 2013 (defined daily dose per 1000 psychiatric inpatients per day)

| Drug                  | 2004  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  |
|-----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Perphenazine          | 1.39  | 1.55  | 2.04  | 2.23  | 2.39  | 2.38  | 1.90  | 2.57  | 2.64  | 2.55  |
| Thoridazine           | 0.42  | 0.44  | 0.27  | 0.32  | 0.32  | 0.31  | 0.28  | 0.16  | 0.17  | 0.18  |
| Clozapine             | 6.37  | 5.27  | 8.37  | 5.83  | 6.59  | 5.58  | 6.66  | 6.64  | 5.37  | 4.63  |
| Levomepromazine       | 0.77  | 0.95  | 0.84  | 0.7   | 1.19  | 0.61  | 0.82  | 0.77  | 0.79  | 1.05  |
| Fluphenazine          | 70.25 | 61.17 | 58.92 | 57.69 | 56.86 | 58.00 | 54.74 | 65.53 | 56.78 | 57.56 |
| Properciazine(Periciazine) | 0.12  | 0.14  | 0.12  | 0.18  | 0.22  | 0.16  | 0.15  | 0.13  | 0.18  | 0.17  |
| Chlorpromazine        | 4.00  | 4.41  | 3.90  | 3.31  | 4.02  | 3.65  | 3.69  | 3.40  | 3.05  | 1.52  |
| Haloperidol           | 42.37 | 42.31 | 37.64 | 45.34 | 45.75 | 47.32 | 45.83 | 49.04 | 40.63 | 38.95 |
| Flupentixol           | 0.45  | 0.32  | 0.25  | 0.26  | 0.28  | 0.18  | 0.17  | 0.29  | 0.11  | 0.15  |
| Zuclopenthixol        | 21.05 | 14.26 | 16.26 | 18.79 | 18.83 | 19.09 | 17.59 | 19.21 | 17.94 | 17.58 |
| Pimozide              | 0.03  | 0.01  | 0.07  | 0.15  | 0.13  | 0.12  | 0.12  | 0.12  | 0.01  | 0.24  |
| Sulpiride             | 1.40  | 1.56  | 2.59  | 1.62  | 1.62  | 1.62  | 1.62  | 1.62  | 1.62  | 1.62  |
| Total                 | 148.62| 132.39| 131.27| 136.38| 138.11| 138.99| 134.64| 148.89| 128.81| 125.57|
paliperidone were among the less tolerated drugs. Hence, the higher administration rates for olanzapine, quetiapine and clozapine in our study could be explained by better efficacy and tolerability. However, olanzapine and clozapine induce significantly more weight gain than most other antipsychotics, and iloperidone, sertindole, quetiapine, risperidone and paliperidone are associated with significantly more weight gain than aripiprazole, amisulpride and ziprazidone. In addition, there are mixed results for the sedative effect that was found to be the highest for clozapine, but low for both amisulpride and paliperidone. Therefore, all-cause discontinuation, which encompasses both efficacy and tolerability, is a more suitable measure of drug acceptability and utility. From this perspective, the significantly lower rates of all-cause discontinuation for olanzapine, quetiapine and clozapine compared to other atypicals [8] could account for their increasing consumption. This explanation is supported by RCTs demonstrating that patients with schizophrenia discontinue antipsychotics mainly due to inefficacy rather than side effects, i.e., patients prioritize efficacy over tolerability [23].

Apart from the above explanations, our findings could be accounted for by the fact that clinicians tend to increase dosing of medications in an attempt to achieve a better response. Prescription of high doses of antipsychotics is common in hospitalized patients, despite the lack of evidence for such an approach [24]. For example, olanzapine and quetiapine are well tolerated at high doses, and these doses may also produce greater improvement [25, 26], whereas increasing the dose of risperidone beyond the optimal recommended dose range (4–8 mg/day) does not improve effectiveness, but exposes the patients to higher rates of side effects [27]. It is possible that our observation of increased administration trends for olanzapine and quetiapine and decreased utilization of risperidone reflect the changes in clinical practice with regard to antipsychotic dosages owing to clinicians’ greater awareness of the balance between clinical benefit and emergent side effects [28].

Another possible explanation for the revealed trends lays in the popular practice among clinicians of administering more than one atypical to enhance treatment effectiveness (polypharmacy). The practice of polypharmacy in the treatment of psychoses is common across countries and clinical settings: [29], 28 % to 57 % of people with schizophrenia reported using more than one antipsychotic during a one-year follow-up [30, 31]. More specifically, Novick and colleagues [32] reported that only 66.8 % of patients treated with olanzapine, 52.6 % treated with amisulpride and 43.4 % treated with quetiapine maintained their baseline monotherapy over 12 months. Thus, polypharmacy of large doses of several antipsychotics may be partly responsible for the increased utilization trends in Israel, at least for antipsychotics. Hence, systematic studies on appropriate dosing of antipsychotics in conjunction with augmentation strategies are warranted.

Health policy-related factors may also explain the observed trends. As mentioned, all atypical antipsychotic agents, except sertindole, are included in the Israeli list of approved medications that are provided at no cost to patients by the mandatory health insurance funds. The inclusion of any pharmaceutical product in the drug list is accompanied by approved indications and limitations detailed in the National Health Insurance Law. Unfortunately, the process of approval of the atypical antipsychotics was made mainly at a bureaucratic level and without the input of an expert committee and thus was not clinical in nature. From 2004 throughout 2013, the clinical indications for dispensation of atypical antipsychotics were extended by the “health basket” committee in the Ministry of Health. Thus, atypical antipsychotics were granted priority over other treatment options (typical antipsychotics) encouraging the use of atypicals, and consequently, increasing their rates of administration. This was true for olanzapine, quetiapine and amisulpride which were approved in 2006 as first-line treatment for both schizophrenia and bipolar disorder. Similarly, the administration of paliperidone and aripiprazole rose following their inclusion in the approved drug list in 2009 and 2010, respectively.

Atypical (second-generation) antipsychotics were introduced in Israel in 2000 and their cost was substantially higher than that of first-generation antipsychotics. Restricted use of atypicals reflected the significant budget constraints of psychiatric hospitals. Despite the burden, clinical reality required the use of atypicals to attenuate the exposure to serious adverse effects (mainly extrapyramidal) of the first-generation antipsychotics. However, it

### Table 3 The relationship (%) between DDD of typical and atypical antipsychotics covered by Israel’s national health care system, 2004 – 2013 (defined daily dose per 1000 psychiatric inpatients per day)

| Year | Typical DDD Total | Percent | Atypical DDD Total | Percent |
|------|-------------------|---------|--------------------|---------|
| 2004 | 148.62            | 53.7    | 128.1              | 46.3    |
| 2005 | 132.39            | 51.2    | 126.4              | 48.8    |
| 2006 | 131.27            | 43.5    | 170.8              | 56.5    |
| 2007 | 136.38            | 47.6    | 149.9              | 52.4    |
| 2008 | 138.11            | 48.5    | 146.8              | 51.5    |
| 2009 | 138.99            | 43.9    | 177.7              | 56.1    |
| 2010 | 134.64            | 48.1    | 145.4              | 51.9    |
| 2011 | 148.89            | 45.9    | 175.5              | 54.1    |
| 2012 | 128.81            | 34.0    | 250.3              | 66.0    |
| 2013 | 125.57            | 36.2    | 221.7              | 63.8    |

- **Typicals** include: amonitral, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone, ziprasidone, ziprazidone.
- **Atypicals** include: aripiprazole, amisulpride, iloperidone, iloperidone extended release, olanzapine, quetiapine, risperidone, ziprazidone.

---
is of note that treatment with atypical antipsychotics is associated with obesity, diabetes and metabolic syndrome. The medical care system’s cost of reducing EPS by going over to second generation atypical antipsychotics in terms of metabolic abnormalities should be investigated in future studies. It is possible that the results of such studies could reveal a historic mistake made in psychiatry.

It should be noted that the initial high costs of all new atypical antipsychotics substantially decreased five years following approval, which coincided with the introduction of their generic counterparts. Thus, the increase in administration of atypicals can be attributed in part to the registration of less expensive generic drugs in Israel. The introduction of generic olanzapine in 2011 most likely accounted for the sharp increase in its administration owing to the reduced cost.

The trends in the use of atypical antipsychotics reported in this study provide useful information for policy development for the treatment of patients with SMI, patients resistant to conventional treatment or those experiencing serious adverse effects.

Policy implications for the near future
The National Health Insurance Law, introduced in Israel in 1995, exposed a gap between provision of physical and mental health services. Article 2 of the Law assigned responsibility to the Health Maintenance Organizations (HMOs) for physical health services. However, according to Article 3, the State remained responsible for mental health services. The Mental Health Service System Reform [33] declared that the State would finance psychiatric hospitals until July 2015, after which financial responsibility would be transferred to the HMOs. Psychiatric hospital budgets include salaries for staff (based on collective agreements) and for all hospital operations, including medications.

Given the above considerations, the Israeli Ministry of Health allocated an earmarked 10 million NIS annual budget for atypical antipsychotic agents. Over the last decade, the number of new atypical antipsychotics increased and their costs decreased following the introduction of generic forms of some of the atypicals. These parallel processes allowed the psychiatric hospitals to extend the use antipsychotics and remain within the constraints of the existing budget.

The Mental Health Reform implemented fundamental changes in the economic status of state psychiatric hospitals: HMOs now finance all psychiatric hospitalizations, and the former state-owned hospitals no longer receive government funding. Prior to the Mental Health Reform, psychiatric hospitals received an earmarked budget for atypical antipsychotics (approximately 14.5 million NIS total, or 2400 NIS per bed). Following implementation of the reform, this special budget was cancelled and the allotment was added to the cost per day of hospitalization. Considering that most of the drug company profits are from medications administered in ambulatory care, negotiations are under way with the pharmaceutical companies to reduce the cost of inpatient medications. Economic limitations and inevitable budget deficits will undoubtedly impact the choice of inpatient antipsychotic treatment.

The use of clozapine will be extended for both acute and chronic resistant patients for two reasons. First, clozapine is the most effective treatment for schizophrenia patients who are resistant to other atypicals, and second, its generic form is relatively inexpensive. It is therefore expected that the HMOs will encourage psychiatric hospitals to initiate the treatment with clozapine as early as possible, an advantageous scenario for schizophrenia patients and their families.

Long-acting forms of atypical antipsychotics will be prescribed mainly in community health-care settings as maintenance treatment for schizophrenia and will be prescribed in hospitals just prior to discharge in line with HMO policy.

In sum, the trends detected in this study support several recommendations for policy development regarding the treatment of patients with SMI, patients resistant to conventional treatment or those experiencing serious adverse effects of conventional treatment.

Study limitations
The calculation of the defined daily dose (DDD) adjusts total consumption of atypical antipsychotic medications by the number of psychiatric inpatients nationwide. Hence, variation in DDDs over time could reflect changes in the volume of inpatients with disorders other than schizophrenia, many of whom are less likely to be treated with atypical antipsychotics. This could account for the large year-to-year swings in DDDs, if the total psychiatric inpatient population varies more over time than the size of the inpatient population with schizophrenia.

In addition, our study included only inpatients in all psychiatric settings (i.e., the most severe cases), hence the obtained results cannot be generalized to outpatients with SMI or the general population. As previously mentioned, this study sample was chosen because of the availability of reliable data on atypical antipsychotic utilization in the inpatient population and the reliable statistics of psychiatric hospitalizations. Future studies targeting outpatient populations are warranted.

Another limitation is the use of an aggregate, non-patient level of data. Due to this limitation the contribution of growth in polypharmacy, increasing doses over time, or inclusion of more patients receiving such treatments could not be assessed. Furthermore, the aggregate data evaluation cannot scrutinize explanations for changes in the prescribing patterns of atypical antipsychotic agents. Some of the
factors that drive drug-specific prescribing trends are not observable in aggregate data. As a result, a further study could focus on explanatory factors that can be related to the aggregate data, such as the timing of introduction of various drugs to the market, and the dates that they were first introduced as generics. A timeline with those changes could add considerable value to the study by illustrating which regulatory changes relate to which trends. Unfortunately, we do not have reliable information regarding the timing of drug and generic entry. The use of patient-level data is an interesting topic for future study, in which the number of patients using each medication could be analyzed.

Finally, the time-frame for the trends of recently marketed atypicals (paliperidone, iloperidone, and sertindole) is shorter than for the older atypicals, such as clozapine, olanzapine and risperidone. Further research is needed to explore the consumption trends for the novel atypicals in the long-term.

It appears that the growth in the use of atypicals represents both substitution for typicals as well as a supplementation (expansion of the total use of antipsychotics), namely, use of atypicals for patients or indications where they were reluctantly using typicals. A 10-year retrospective study on the trends in prescribing psychotropic drugs to children and adolescents within an inpatient adolescent psychiatric ward in Israel has demonstrated that typical antipsychotic prescriptions decreased by 35.5% while the prescriptions of atypical antipsychotics increased by 51.5% [34]. Similar analysis of the trends in the types of antipsychotic prescribed to schizophrenia patients over a 3-year period has been found in two large mental health catchment areas of Auckland (Australia): with an 18.6% increase in atypical antipsychotics and a 23.3% decrease in both intramuscular and oral typical antipsychotics [35].

Conclusion

The reasons for the increasing administration of atypical antipsychotics, as well as the decrease in the consumption of typicals, in the psychiatric inpatient population over the last decade are not totally clear. Similiar trends have also been observed in other countries among psychiatric outpatients. These trends seem to be related to both substitution and supplementation. In the absence of evidence on the nature of the increasing trends in the utilization of atypical antipsychotics among inpatients, the possible contribution of their extended off-label prescription or potential augmentation strategies of combinations of several antipsychotics (polypharmacy) cannot be ruled out. Rigorous detailed research in dosing of antipsychotics and their combined use is needed before firm conclusions for solid policy changes can be drawn.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AMP, EM and MB-L conceived of the project with input on the design from IB. EM and MB-L conducted the statistical analysis. AMP wrote the first draft of the manuscript and AW and ES provided significant input in the drafting of the final version of the manuscript. All authors contributed to and have approved the final manuscript.

Authors’ information

Alexander M. Ponizovsky, MD, PhD, is a psychiatrist and former Advisor on Mental Health Research at the Ministry of Health’s Mental Health Services Division (2001–2015). He is now an independent researcher. He is author of more than 150 scientific publications in diverse areas of psychiatry and related sciences including psychopharmacoepidemiology; suicidology; schizophrenia and addiction disorders; hospital and community-based mental health services and rehabilitation; evaluation for different treatment programs with regard to quality of life and psychosocial outcomes assessment; psychological distress, psychosocial resources, and treatment maintenance; migration and mental health research.

Michal Ben-Laish, BSc, is a biologist and pharmacist, who has worked as part of the Ministry of Health’s Health Technology Assessment Division and the Drug Registration Department in the Pharmaceutical Division (2012–2015). She worked as part of a team for providing accessibility of information about drugs, from the National List of the publicly funded Health Services in Israel. Igor Barash, MD, MHA, is Deputy Director of Eitanim Psychiatric Hospital. Previously (2010–2014), he was head of the Clinical Department, Mental Health Services, Ministry of Health.

Prof. Abraham Weizman obtained his MD degree from the Sackler Faculty of Medicine at Tel Aviv University in Israel and subsequently spent 2 years as a visiting scientist at NIMH in Bethesda, MD. He is a Professor of Adult and Child Psychiatry, the Head of the Research Unit at Geha Mental Health Center and Director of the Felsenstein Medical Research Center, all affiliated with the Sackler Faculty of Medicine, Tel Aviv University. Professor Weizman investigates brain mechanisms of mental disorders. In recent years he has focused on neurodevelopmental disorders, the development of new strategies for the treatment of psychotic disorders and psychopharmacology of mental disorders.

Dr. Eyal Schwartzberg, RPh, MSc, PhD, MRPharmS, is a qualified pharmacist and regulator. Since 2012 he has served as the State’s Chief Pharmacist and as the Head of the Pharmaceutical Division in the Israeli Ministry. In this capacity he is responsible for setting regulations and policies for, the pharmaceutical industry and the pharmacy profession. Dr. Schwartzberg is also senior lecturer in clinical pharmacy and pharmacy practice at the School of Pharmacy at Ben Gurion University. Dr Schwartzberg has extensive experience in clinical pharmacy, risk management, benefit risk analysis and crisis management.

Acknowledgments

We thank the staff of the SAREL drug warehouse for assistance with data collection and two anonymous reviewers for their thoughtful and contributing comments.

Funding sources

A.M. Ponizovsky was supported in part by the Ministry of Immigrant Absorption.

Author details

1Mental Health Services, Ministry of Health, Jerusalem, Israel. 2Pharmaceutical Administration, Ministry of Health, Jerusalem, Israel. 3Research Unit, Geha Mental Health Center and Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 453/1 Ha-Kinor St., Ma’ale Adumim 9837125, Israel.

Received: 9 April 2016 Accepted: 3 May 2016 Published online: 15 June 2016
References

1. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255–62.

2. Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11:95–106.

3. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27:515–29.

4. Wright BM, Elaad 3rd EH, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacother. 2013;33:544–59.

5. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393–406.

6. Hartling L, Abou-Setta AM, Dursun S, et al. Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications: A Systematic Review and Meta-analysis. Ann Intern Med. 2012;157:498–511.

7. Leucht S, Cipriani A, Spinnell L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stafuf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.

8. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are asenapine- generation antipsychotics? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429–47.

9. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for Anatomical Therapeutic Chemical (ATC). Classification Research System. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Report No. S; 1997.

10. Divac N, Tosevski DL, Babic D, Dujic D, Prostran M, Samardzic R. Trends in consumption of psychiatric drugs in Serbia and Montenegro 2000–2004. Pharmacoepidemiol Drug Saf. 2006;15:935–8.

11. Crystal S, Olsson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28:770–81.

12. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaeco-epidemiological studies. Acta Psychiatr Scand. 2010;121:4–10.

13. Stephenson CP, Karanges E, McGregor IS. Trends in the utilization of antipsychotic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry. 2013;47:74–87.

14. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84.

15. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorders: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23:346–88.

16. Cooper WO, Hickson GB, Fuchs C, Arboagat PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158:753–9.

17. Hollingsworth SA, Sinkdj DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002–2007. Aust N Z J Psychiatry. 2010;44:372–7.

18. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cimboli P, Baldessarini RJ. Antipsychotic drug use: McLean Hospital. 2002. Hum Psychopharmacol. 2005;20:355–8.

19. Centorrino F, Ventriglia A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol. 2010;25:179–86.

20. Ministry of Health. Mental Health in Israel. Statistical Annual. Jerusalem: Ministry of Health; 2004–2013.

21. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, 2010. http://www.whocc.no/atc_ddd_index/ Accessed 7 May 2016.

22. Israeli Central Bureau of Statistics. Statistical Abstract of Israel 2000–2008. http://www1.cbs.gov.il/www/publications13/yarhon0713/pdf/b1.pdf. Accessed 7 May 2016.

23. Nussbaumb A, Stroups TS, Paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008;6:CD003639. doi:10.1002/14651858.CD003639.pub2. 2CD003639.

24. Adesola A, Anoie J, Erobhie P, James B. Prevalence and correlates of "high dose" antipsychotic prescribing: findings from a hospital audit. Ann Med Health Sci Res. 2013;5:6–6.

25. Breier A, Meehan K, Birkett M, David S, Ferrichl L, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441–8.

26. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Serquei Study Group. Arch Gen Psychiatry. 1997;54:549–57.

27. Peukers J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166:712–26.

28. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10:280–91.

29. Sun F, Stock EM, Copeland LA, Zeber JE, Ahmedian BK, Morissette SB. Polypharmacy with antipsychotic drugs in patients with schizophrenia trends in multiple health care systems. Am J Health Syst Pharm. 2014;71:728–38.

30. Waterreus A, Morgan VA, Castle D, Galletly C, Jablensky A, Di Pinzio P, et al. Medication for psychosis–consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46:762–73.

31. Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M. Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan. Clinicoecon Outcomes Res. 2012;4:13–9.

32. Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study. J Nerv Ment Dis. 2012;200:637–43.

33. Aviram U. Promises and pitfalls on the road to a mental health reform in Israel. Isr J Psychiatry Relat Sci. 2010;47:171–83.

34. Gilat Y, Ben-Dor DH, Magen A, Wolvlick V, Vekslerchik M, Weizman A, Zalman G. Trends in prescribing of psychotropic medications for inpatient adolescents in Israel: a 10 years retrospective analysis. Eur Psychiatry. 2011;26:265–9.

35. Wheeler A, Humberstone V, Robinson G. Trends in antipsychotic prescribing in schizophrenia in Auckland. Australas Psychiatry. 2006;14:169–74.